ARIDIS PHARMACEUTICALS, LLC

LOS GATOS, CA · Biotech · Public

Oral thin film vaccine dosage form with ambient-temperature stability using proprietary stabilization formulation

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: LOS GATOS, CA
Latest Form D: $4.8M, Dec 2022
Total capital: $56.9M

Federal grants: $283K; 1 award · 2015; Rank in peer group#8 of 20
Private capital raised: $56.6M; 7 Form D · last Dec 2022; 46 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Dec 2022Private capital raisedForm D · SEC · 7th filing$4.8M
Oct 2022Private capital raisedForm D · SEC · 6th filing$8M
Oct 2020Private capital raisedForm D · SEC · 5th filing$8.4M
Dec 2016Private capital raisedForm D · SEC · 4th filing$13.6M
Aug 2016Private capital raisedForm D · SEC · 3rd filing$15.2M
Nov 2015Private capital raisedForm D · SEC · 2nd filing$3M
May 2015Federal grantHealth and Human S · Phase I · Stable Vaccines Delivered on Oral Thin Films$283K
Jul 2014Private capital raisedForm D · SEC · 1st filing$3.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 20 peers

Line = median

Biotech · Material

Federal grants#8 · top 40%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Vu TruongResearcherExecutive Officer, DirectorLinked by $283K in grants as PI
Craig GibbsDirectorNamed in SEC Form D filings
Eric PatzerDirectorNamed in SEC Form D filings
Fred KurlandExecutive OfficerNamed in SEC Form D filings
Isaac BlechDirectorNamed in SEC Form D filings
John BorgesonExecutive OfficerNamed in SEC Form D filings

Show all 14 people

John HamiltonDirectorNamed in SEC Form D filings
Mike NazakExecutive OfficerNamed in SEC Form D filings
Paul-Andre de LameExecutive OfficerNamed in SEC Form D filings
Robert CoughlinDirectorNamed in SEC Form D filings
Robert RuffoloDirectorNamed in SEC Form D filings
Robert Ruffolo, Jr.DirectorNamed in SEC Form D filings
Susan Windham-BannisterDirectorNamed in SEC Form D filings
Vu TroungExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

ACUMEN PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
StrideBio, Inc.Similar federal contract value in Biotech · null in contracts
Alveus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
FirstString Research, IncSimilar federal contract value in Biotech · null in contracts
Clover Biopharmaceuticals, Ltd.Similar federal contract value in Biotech · null in contracts
Carterra, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.